Optimi Health exports psilocybin capsules to Australia

Mr. Dane Stevens reports OPTIMI HEALTH COMPLETES PSILOCYBIN EXPORT TO AUSTRALIA FOR TREATMENT RESISTANT DEPRESSION Optimi Health Corp. has exported its GMP-manufactured (good manufacturing practice) natural five-milligram psilocybin capsules to Australia for the treatment of patients diagnosed with treatment-resistant depression (TRD) under Australia's Authorised Prescriber Scheme. The shipment represents Optimi's second finished drug product supplied into Australia's Authorised Prescriber Scheme, alongside the company's 40-milligram and 60-milligram MDMA (3,4-methylenedioxymethamphetamine) capsules for posttraumatic stress disorder (PTSD). "Optimi's five-milligram naturally derived psilocybin capsules are now available to patients in Australia suffering from treatment-resistant depression," said Dane Stevens, chief executive officer and co-founder of Optimi Health. "Supplying pharmaceutical-grade psilocybin outside of traditional clinical trials within a nationally regulated framework is an important milestone for our team and shareholders. Optimi is purpose built to control the full production life cycle -- cultivation, extraction, encapsulation and packaging -- through our proprietary GMP process, ensuring consistency, quality and dependable supply as clinical access expands." Psilocybin-assisted therapy in Australia is available through authorized clinics, including programs supported by the Department of Veterans' Affairs (DVA). Under the current policy framework, the DVA may reimburse eligible patients for the full cost of psychedelic-assisted therapy, including both the medicine and associated psychotherapy. Optimi manufactures its finished psilocybin drug product under a Health Canada-issued drug establishment licence, authorizing pharmaceutical-grade production and international export for prescription use. Treatment outcomes are being captured through Australia's national patient registry in partnership with the Australian National University (ANU). Clinicians, hospital networks and authorized programs operating under the Authorised Prescriber Scheme may seek information regarding access through Mind Medicine Australia at [email protected]. For global enquiries outside of Australia, please contact [email protected]. About Optimi Health Corp. Optimi Health is a leading producer of prescribed psychedelic treatments for mental health therapies. As a Health Canada-licensed, GMP-compliant pharmaceutical manufacturer producing validated MDMA and botanical psilocybin products from two 10,000-square-foot facilities in British Columbia, Optimi supplies active pharmaceutical ingredients and finished dosage forms to regulated channels, with products currently in market for prescription use in Australia through the Authorized Prescriber Scheme and accessible in Canada through the Special Access Program. We seek Safe Harbor.